ResMed Inc. (RMD): Price and Financial Metrics

ResMed Inc. (RMD)

Today's Latest Price: $142.29 USD

5.00 (-3.39%)

Updated Apr 1 4:10pm

Add RMD to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

RMD Stock Summary

  • With a market capitalization of $19,531,964,862, Resmed Inc has a greater market value than 93.03% of US stocks.
  • RMD's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 871.78 -- higher than 96.47% of US-listed equities with positive expected earnings growth.
  • The price/operating cash flow metric for Resmed Inc is higher than 94.01% of stocks in our set with a positive cash flow.
  • Stocks that are quantitatively similar to RMD, based on their financial statements, market capitalization, and price volatility, are A, CSGP, CERN, EBAY, and HPE.
  • RMD's SEC filings can be seen here. And to visit Resmed Inc's official web site, go to
RMD Daily Price Range
RMD 52-Week Price Range

RMD Stock Price Chart More Charts

RMD Price/Volume Stats

Current price $142.29 52-week high $177.99
Prev. close $147.29 52-week low $96.81
Day low $138.16 Volume 960,105
Day high $145.38 Avg. volume 763,677
50-day MA $159.31 Dividend yield 1.06%
200-day MA $143.57 Market Cap 20.58B

ResMed Inc. (RMD) Company Bio

ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and management of respiratory disorders with a focus on sleep-disordered breathing. The company was founded in 1989 and is based in San Diego, California.

RMD Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

We started the process of determining a valid price forecast for Resmed Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Resmed Inc ranked in the 15th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Resmed Inc ended up being:

  • The company's debt burden, as measured by earnings divided by interest payments, is 13.19; that's higher than 74.65% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet reveals debt to be 6% of the company's capital (with equity being the remaining amount). Approximately only 14.76% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • RMD's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 54.16% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

GMED, VAR, TECH, A, and ELMD can be thought of as valuation peers to RMD, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

RMD Latest News Stream

Event/TimeNews Detail
Loading, please wait...

RMD Latest Social Stream

Loading social stream, please wait...

View Full RMD Social Stream

RMD Price Returns

1-mo -15.68%
3-mo -8.65%
6-mo 8.00%
1-year 37.02%
3-year 106.42%
5-year 113.48%
YTD -7.98%
2019 37.85%
2018 36.38%
2017 39.06%
2016 18.01%
2015 -2.29%

RMD Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full RMD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.5106 seconds.